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ABSTRACT 
The CDC states that there has been a dramatic increase in obesity from 1990 to 
2010. Type-II diabetes and obesity prevalence are increasing worldwide.  Often, 
obesity and Type-II diabetes are concurrent, and predispose individuals to 
development of fatty liver disease, referred to as Non-alcoholic fatty liver disease 
(NAFLD).  Perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) 
are two commonly studied perfluorinated compounds (PFC’s) that are considered 
environmental toxicants that have the potential to elicit diabetic and NAFLD 
phenotypes. This dissertation presents novel findings of gaps within the literature to 
date. Traditionally, diabetes and obesity have been discussed in regard with genetics, 
diet and old age.  Now, risk factors that also need to be considered are environmental 
chemicals. We found that PFOS elicits an insulin-resistant phenotype in adult mice, 
where they were not utilizing glucose as readily compared to the controls.  The effect 
of PFOS on therapeutic management interventions has not previously been looked at.  
Here, we show that PFOS interferes with the Metformin-induced decrease in glucose. 
We also found a vast increase in the hepatic triglycerides with PFOS exposure.  In this 
thesis, PFOS was administered in a sub-chronic low dose (100μg/kg) daily to mice fed 
ad libitum or placed on caloric restriction (CR) for five weeks.  In the cohort we 
generated, we observed that PFOS exposure increased hepatic lipid content in mature 
male mice fed ad libitum and dampened the observed CR-induced decrease in hepatic 
lipids.  PFOS administration did not affect glucose tolerance in ad libitum fed mice, 
but did interfere with CR-induced improvement of glucose tolerance.  This was further 
associated with suppression of IRS-1 mRNA expression in liver.  As hepatic lipid 
  
content is closely tied to insulin and glucagon signaling for hepatic glucose 
production, it was determined whether the observed effects in vivo were due to PFOS-
stimulated hepatic glucose production.  Using cultured mouse hepatocytes under low 
glucose conditions, it was evaluated whether PFOS could enhance glucagon-
stimulated glucose production. PFOS stimulated hepatocyte glucose production and 
also enhanced glucagon-induced glucose production.  Furthermore, in HEPG2 cells, 
PFOS exposure (25 and 250 µM) significantly increased glucose output and AiCar, 
which suppresses glucose production, was ineffective in the presence of PFOS.  These 
findings provide a mechanistic explanation for the decreased glucose tolerance in our 
in vivo mouse cohort.  PFOS increases glucose output from the in vitro models, even 
when challenged with metformin or AiCar, as well as, decreases the glucose 
utilization in the in vivo mouse study suggesting that it has a glucagon-like effect.   
 PFOA is a perfluorinated carboxylic acid also commonly found in the 
environment. According to the EPA, low levels of PFOA are widely distributed in 
environmental media (Houde et al., 2011; Gewertz et al., 2013) and in the blood of the 
general United States population. The EPA states that PFOA is a known liver toxicant, 
development toxicant, and carcinogen in rodents.  It has been detected in human liver, 
kidney and adipose tissue ranging from 0.3 to 3.8ng/g with the highest concentrations 
within the liver (Maestri et al., 2006). In another study, PFOA is considered an 
obesogen to mid-aged mice where insulin and leptin levels were altered at a very low 
concentration (Hines et al., 2009). PFOA is a Potent activator of peroxisome-
proliferator activated receptor-alpha (Ppar-α) contributing to oxidative stress and 
activation of fatty acid oxidation pathways in hepatocytes. Given its persistence, the 
  
purpose of this study was to evaluate whether PFOA treatment affects fatty acid 
oxidation, lipid synthesis, and antioxidant response gene expression in adipose tissue 
in adult male mice. Utilizing an exposure paradigm characterized by the 
Environmental Protection Agency, adult male mice were treated with 1.0 or 3.0 mg 
PFOA ammonium salt/kg for 7 days. Adipose tissue was collected and total RNA was 
isolated. Analysis of mRNA was completed by quantitative PCR. For the most part, 
gene expression in adipose tissue from vehicle- and PFOA-treated mice was similar. 
Literature lacks data on PFOA in adipose tissue and in human health, which continue 
to be discovered. Given its persistence, longer exposure periods and protein expression 
changes should be examined.
 v 
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PREFACE 
The following thesis project is in Manuscript Format.  Based on our previous lab 
findings, the initial goals of this thesis project were to evaluate different models for 
changes and regulation of Nrf2, a transcription factor.  However, after interesting 
observations with perfluorinated compounds (PFC’s), my thesis evolved into a more 
focused and mechanistic study on Perfluorooctanesulfonic acid (PFOS), a major PFC.   
The bulk of the thesis work has been to understand whether PFOS exposure can 
interfere with the benefits of caloric restriction in vivo or in vitro.  Epidemiology 
studies associating PFOS exposure with altered metabolics has further provided 
justification for studying PFOS effects.   
 Because the thesis is manuscript format, there have been experiments not 
included in the manuscript, but still essential to key observations of the thesis work.  
These have been included.  Appendix material will also present findings for PFOS and 
PFOA with regard to adipose tissue and gene expression, along with work performed 
regarding the Nrf2 activating compounds, oleanolic acid (OA) and butylated 
hydroxyanisole (BHA), on interaction with a lithogenic diet that I generated early in 
my graduate career.     
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Chapter 1 
Introduction to liver disease and perfluorinated compounds 
Non-alcoholic fatty liver disease (NAFLD) statistics and etiology 
NAFLD is a common chronic liver disease that is increasingly growing within the 
general population affecting 30% of adults, 20% of children and 69% of type 2 
diabetic (T2D) patients in the United States (Ahmed et al., 2015; Leite et al., 2009; 
McCullough, 2006).  Features of metabolic syndrome are commonly found in NAFLD 
such as obesity (67-71%), disturbed lipid profiles (57-68%) and hypertensive (36-
70%) (Ahmed et al., 2015).  NAFLD is defined by evidence of steatosis by imaging or 
histology without any secondary hepatic fat accumulation such as alcoholic 
consumption (Chalasani et al., 2012).  Major risk factors for NAFLD include obesity, 
type-2 diabetes (T2D) and dyslipidemia (Chalasani et al., 2012).  More than 90% of 
NAFLD patients have insulin resistance or feature metabolic syndrome (Ahmed et al., 
2015). Non-alcoholic steatohepatitis (NASH) is the most severe histological form of 
progress to cirrhosis with 20-30% of these patients experiencing a liver-related death 
(McCullough, 2006). 
Mechanisms contributing to 
NAFLD 
NAFLD can result from 
insufficient adiponectin release 
from adipose tissue (Polyzos et al., 
2009). Adiponectin levels decrease 
as fat mass increases, thereby 
Figure C1-1.  Schematic depicting the overall outcome 
of decreased circulating adiponectin levels. 
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resulting in subsequent signal transduction consequences within cells (Polyzos et al., 
2009).  One of these consequences is insulin resistance (IR) (Polyzos et al., 2009).  
With IR, glucose uptake is decreased and fatty acid oxidation are decreased while 
gluconeogenesis, de novo synthesis lipogenesis are increased creating a cycle of 
obesity, IR and the subsequent fatty liver (Polyzos et al., 2009) (Figure C1-1). A 
dysregulation and an imbalance of adipokines/cytokines are abundantly found in 
NAFLD and have been shown to lead to IR and fatty liver (Watanabe et al., 2008; 
Takei et al., 2006; Jarrar et al., 2008).  Adiponectin is an adipose-specific adipokine 
that acts on amp-activated protein kinase (AMPK) within the liver protecting from 
insulin resistance (IR) and ultimately, fatty liver (Polyzos et al., 2009) (Figure C1-2). 
Upon activation, AMPK down-regulates sterol regulatory element-binding proteins 
(Srebp), which are a group of membrane-bound transcription factors that regulate lipid 
synthesis (Kohjima et 
al., 2008).  Specifically, 
Srebp1c regulates the 
expression of genes 
encoding lipogenic 
enzymes such as acetyl-
CoA carboxylase (Acc1) 
and fatty acid synthase 
(Fas)  (Kohjima et al., 
2008).  In NAFLD, as 
adiponectin is decreased, 
Figure C1-2: Schematic depicting molecular mechanisms 
contributing to NAFLD. 
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AMPK activation is also decreased resulting in Srebp1c activation and lipid synthesis 
via Acc1 and Fas within the liver eliciting a fatty liver (Kohjima et al., 2008) (Figure 
C1-2).   
Therapeutic strategies for NAFLD Treatment 
The recommended therapeutic intervention to treat NAFLD is with diet and exercise, 
which have the ability to reverse hepatic lipid accumulation (Chalasani et al., 2012).  
It has been shown that a calorically restricted (CR) diet with exercise decreases the 
hepatic steatosis and serum lipids in overweight patients with NAFLD (Larson-Meyer 
et al., 2008).    In earlier studies, it is suggested that CR with or without exercise 
decreases liver fat and liver enzymes with no difference between CR groups with the 
CR and exercise groups (Yoshimura et al. 2014; Straznicky et al., 2012; Tamura et al., 
2005; Larson-Meyer et al., 2008).   In a randomized-controlled study trial of NAFLD 
patients, intervention with diet, after 12-months, 64% patients were in NAFLD 
remission which includes a reduction in body weight and total cholesterol levels 
(Wong et al., 2013).   NAFLD can be reversed with CR intervention. 
Molecular Mechanisms by which CR decreases Liver Fat 
The response to CR hinges upon a cellular metabolic shift in which AMPK is a central 
mediator.  CR induces phosphorylation of AMP-activated protein kinase (AMPK) 
upon redox status (high AMP:ATP ratio) (Figure C1-3).   AMPK is a regulator of 
hepatic metabolism in energy balance by promoting catabolic pathways and inhibiting 
ATP-consuming pathways and is a good target for the treatment of T2D (Viollet et al., 
2006). AMPK activation is implicated for the benefits of glucose and lipid metabolism 
with exercise, weight loss, and use of anti-diabetes drugs (Towler et al., 2007).  
  
 
4
AMPK inhibits hepatic glucose and lipid synthesis and induces lipid oxidation to 
produce energy (Nerstedt, 2010).   
 
 
 
 
 
 
 
 
 
 
In addition to caloric restriction, metformin has been examined as a pharmacologic 
therapeutic intervention for the management of NAFLD (Mazza et al., 2012).  
Metformin was first introduced in the 1950’s as a first-line T2D drug due to its ability 
to lower gluconeogenesis and ultimately blood glucose levels which increase glucose 
uptake within skeletal muscle as well as fatty acid oxidation within adipose tissue 
(Stumvoll et al. 1995) (Figure C1-4).   
 Metformin is used in the treatment of T2D and activates AMPK in hepatocytes, which 
in turn suppresses lipogenic genes, such as SREBP1c and Acetyl-CoA carboxylase 
(ACC) while increasing insulin sensitivity (Viollet et al. 2012; Zhou et al., 2001).   
Figure C1-3: Schematic depicting molecular mechanisms in caloric restriction 
and excess. 
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Introduction to 
Perfluorinated 
Compounds: 
Perfluorinated 
compounds (PFCs) are a 
group of synthetic 
anthropogenic 
organofluorines widely 
used in various 
industrial applications 
such as stain-resistant coatings for paper and fabric protection, leather, waxes, 
surfactants, emulsifiers, fire-fighting foams, textiles, chromium plating and more 
(Wan et al. 2012, Ziwen et al., 2014).  The main routes of human exposure are 
through ingestion, dermal exposure, inhalation and through drinking water (Saikat et 
al., 2012).  The main route of general population exposure to PFOS is via ingestion of 
fish and drinking water (Saikat et al., 2012).  There has been no evidence reported of 
the transformation of PFOS in soil, sediment or water (Saikat et al. 2012).  
Perfluorinated chemicals have been studied for a couple of decades and are known to 
induce fatty liver in rodents (EPA, 2009a; Hines, et al. 2009; Klaunig, et al. 2003; 
Tardiff, et al. 2009).  Perfluorooctanesulfonic acid (PFOS) is a major 8-carbon PFC 
that is widely studied today. PFOS has been detected in the sera and tissues of 
animals, specifically fish, birds, and marine mammals, and humans worldwide (Giesy 
and Kannan, 2001; Calafat et al., 2007; Lau et al., 2007) and have been correlated 
Figure C1-4. Schematic of the pathogenesis of metformin within 
liver and peripheral tissues.  
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with adverse health effects in rodents and monkeys, including liver effects and 
decreased cholesterol (Lau et al., 2007, Seacat et al., 2002).  PFOS has also been 
associated with energy metabolism disorders due to Ppar activation in rats (Bjork et 
al., 2008). Environmental exposure of PFOA and PFOS to adult humans were 
associated with increased lipid levels (Eriksen et al., 2013; Chateau-Degat et al., 
2010), however, in mice and monkeys, there is a negative correlation with cholesterol 
levels (Seacat et al., 2003; Seacat et al., 2002).  Moreover, in adolescents and adults, 
increased serum PFOS concentration was associated with increased blood insulin, 
assessment of insulin resistance, and beta-cell function (Lin et al., 2009). Altered 
glucose and lipid metabolism has also been described in adult rats exposed to PFOS 
(Lv et al., 2013).   
 Perfluorooctanoic acid (PFOA) is another PFC, but instead of the sulfonate 
moiety, it has a carboxylic acid.  According to the EPA, PFOA has been investigated 
since the 1990s and is now a known liver toxicant (hepatomegaly), development 
toxicant, and carcinogen in rodents. It is detected in serum and tissues of wildlife and 
humans worldwide with an average half-life of 3.5 years in humans (EPA, 2009a; 
Hines, et al. 2009; Klaunig, et al. 2003; Tardiff, et al. 2009). Human studies of PFOA 
are limited, however, trace amounts of PFOA have been detected in adipose tissue 
(0.2ng/kg) (Calafat, et al., 2007).  It is known that PFOA accumulates mostly in liver 
and kidney and is detectable in serum (Hundley et al., 2006; Olsen et al., 2005).  
PFOA exposure has resulted in weight loss with liver injury and lipid metabolism 
disorders in mice (Seacat et al., 2002; Jensen et al., 2008).   
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Levels of PFOA and PFOS were detected in non-occupationally exposed 
general population humans of liver, kidney, adipose tissue, brain, basal ganglia, 
hypophysis, thyroid, gonads, pancreas, lung, skeletal muscle and blood and found 
PFOA ranging from 0.3 to 3.8ng/g and PFOS ranging from 1.0 to 13.6ng/g with the 
highest concentrations within the liver (Maestri et al., 2006).  Low doses of PFOA and 
PFOS have still been suggested to increase hepatomegaly (Wan et al., 2012; Yan et 
al., 2014), which may be due to the induction of peroxisome proliferation through the 
agonistic nature of PFOA and PFOS on Ppar’s (Pyper et al., 2010; Lau et al., 2007; 
Takacs and Abbott, 2007).  However, studies with PFOA administration in Ppar-α-null 
mice still observed increased liver weight and changes in gene expression associated 
with fatty acid metabolism and fat accumulation suggesting Ppar-independent 
mechanisms (Minata et al., 2010; Wolf et al., 2008; Rosen et al., 2008a and b).   
The purpose of these following dissertation studies was to evaluate PFOS and 
PFOA on metabolic tissues of mice treated with these compounds.  The overall goal of 
Manuscript I was to determine whether PFOS exposure interferes with recommended 
therapies to decrease hepatic lipid content that are used to treat NAFLD.  It was 
hypothesized that PFOS administration could interfere with the benefits of CR and 
metformin potentially through targeting AMPK phosphorylation.  Overall, we present 
novel findings illustrating that PFOS administration concurrent with a modest 
reduction in caloric intake thwarted CR-induced decline in hepatic lipids in vivo and 
improvement in glucose tolerance and interfered with metformin-induced glucose 
lowering effects in vitro.  The goal of Manuscript II was to determine whether PFOA 
treatment affects fatty acid oxidation, lipid synthesis, and antioxidant response gene 
  
 
8
expression in adipose tissue.  Results indicate no significant findings of PFOA 
affecting any gene expression within adipose tissue of mice after a 7-day treatment 
with 1.0 or 3.0 mg/kg/day.  
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ABSTRACT 
A combination of caloric restriction (CR), dietary modification, and exercise is 
the recommended therapy to reverse obesity and nonalcoholic fatty liver 
disease. The ability to mount an effective response to caloric restriction 
required to effectively shift hepatic metabolism to fatty acid oxidation depends 
upon induction of pathways, such as AMP- activated kinase (AMPK). PFOS, a 
fluoro-surfactant previously used as a stain repellent and anti-stick material 
increases hepatic lipids in mice following relatively low dose exposures. We 
hypothesized that PFOS administration will interfere with CR-induced 
reduction of hepatic lipids and improve glucose tolerance. Adult male C57BL/6 
mice were fed ad libitum or 25% reduced calorie diet concomitant with either 
vehicle (water) or 100 μg PFOS/kg/day for 6 weeks. PFOS did not significantly 
alter CR-induced weight loss or WAT mass or liver weight over 6 weeks. 
However, PFOS increased hepatic triglyceride accumulation, and hepatic 
triglycerides were higher in PFOS-treated mice that subjected to calorie 
restriction, which was associated with   decreased phosphorylated AMPK 
protein levels in livers of CR mice.  PFOS interfered with CR-induced 
improvement of glucose tolerance with decreased IRS-1 mRNA expression in 
liver.  PFOS induced glucose production in hepatocytes and HepG2 cells, 
which was partially antagonized by the AMPK activating compound, AiCAR.  
Moreover, metformin suppression of gluconeogenesis was not as robust in 
HepG2 cells with PFOS co-treatment. Overall, PFOS administration had 
disruptive effects for hepatic lipids and glucose homeostasis, and interfered 
with beneficial glucose lowering effect of metformin. 
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INTRODUCTION 
 
Obesity and T2D are concurrent, and predispose individuals to development of 
fatty liver disease, referred to as non-alcoholic fatty liver disease (NAFLD) (Li 
et al., 2002). NAFLD is a complex multifactorial disease in the U.S. with 10% 
of children, 30% of adults, 50% of obese, 76% of diabetics and 100% of 
morbidly obese diabetics affected (Eguchi et al., 2013; Naik et al., 2013; 
Reddy and Roa, 2006).  It is characterized by the accumulation of lipids in the 
liver, lipotoxicity and insulin resistance and thus frequently found in people 
with central obesity or diabetes (Naik et al., 2013; Smith and Adams, 2011).  
NAFLD as a disease is considered to be a spectrum – ranging from simple 
steatosis to non-alcoholic steatohepatitis (NASH). Steatosis is the 
accumulation of triglycerides within the hepatic parenchymal cell cytoplasm, 
whereas non-alcoholic steatohepatitis (NASH) consists of classical steatosis 
accompanied by inflammation (Naik et al., 2013; Reddy and Roa, 2006). 
Hepatic lipid accumulation has been shown to lead to decreased insulin 
sensitivity, ultimately leading to insulin resistance, commonly observed in 
diabetes (Montell et al., 2001).  A hallmark characteristic of hepatic steatosis is 
the disequilibrium between de novo lipogenesis, free fatty acid uptake, 
oxidation, esterification and secretion of lipids from the liver (Naik et al., 
2013).  Hepatic lipid accumulation can be attributed to dampened lipid 
utilization via altered mitochondrial oxidation and hepatic lipid export as well as 
excess adiposity and decreased insulin sensitivity (Smith and Adams, 2011).  
Multiple factors are suggested to contribute to NAFLD and environmental 
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exposure has been hypothesized as a potential risk factor for predisposition to 
NAFLD (Cave et al., 2007). 
 
The American Association for the Study of Liver Disease NAFLD treatment 
guidelines recommends dietary modification and/or weight loss as the current 
NAFLD therapeutic strategy (Larter et al., 2013).  The recommended 
therapeutic intervention to treat NAFLD is with diet and exercise, which have 
the ability to reverse hepatic lipid accumulation (Chalasani et al., 2012).  It has 
been shown that a CR diet with exercise decreases the hepatic steatosis and 
serum lipids in overweight patients with NAFLD (Larson-Meyer et al., 2008).  A 
diet with 30% caloric restriction without malnutrition delays the onset of 
multiple diseases such as diabetes, cancer and cardiovascular disease in 
Rhesus monkeys (Colman et al. 2009). A calorie restricted (CR) diet in 
humans on average for 6 years improved metabolism and insulin levels 
(Fontana et al., 2004).  In human studies, diet and exercise were effective in 
the reduction of NAFLD (Oh et al., 2014; Schwenger and Allard, 2014).  In 
addition, caloric restriction mimetics have been examined as potential 
treatments for NAFLD.  For example, Metformin, a commonly used anti-
diabetes drug with some CR mimetic properties has been investigated as a 
potential therapy to treat NAFLD (Maslak et al., 2014), with some positive 
results (Maslak et al., 2014). 
 
CR increases the cellular AMP:ATP ratio, which induces AMP-activated 
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protein kinase (AMPK) activation (Fulco and Sartorelli, 2008).  AMPK is a 
heterotrimeric serine/threonine protein kinase that regulates energy 
homeostasis in metabolic tissues upon high AMP:ATP ratios with 
phosphorylation at the Thr 172 residue of the alpha subunit (Nerstedt, 2010).  
AMPK activation is implicated for the benefits of glucose and lipid metabolism 
with exercise, weight loss, and use of anti-diabetes drugs (Towler et al., 2007).  
AMPK inhibits hepatic glucose and lipid synthesis and induces lipid oxidation 
to produce energy (Nerstedt, 2010). AMPK phosphorylates sterol regulatory 
element binding protein-1c (SREBP-1c) at Ser-327 inhibiting its activity, 
diminishing SREBP1c-mediated lipogenesis reducing hepatic steatosis (Li et 
al., 2013).  CR increases phosphorylation of AMPK, which then activates Sirt1 
deacetylase under certain redox status (Fulco and Sartorelli, 2008).  In 
steatotic livers, there is a decrease in AMPK phosphorylation in rodents (Ha et 
al., 2011).  Under CR, four overweight males displayed increased 
phosphorylated AMPK and SIRT1 in peripheral blood mononuclear cells 
(Kitada et al., 2013).  AMPK is a regulator of hepatic metabolism in energy 
balance by promoting catabolic pathways and inhibiting ATP-consuming 
pathways and is a good target for the treatment of T2D (Viollet et al., 2006). 
Metformin is used in the treatment of T2D and activates AMPK in hepatocytes, 
which in turn suppresses lipogenic genes, such as SREBP1c and Acetyl-CoA 
carboxylase (ACC) (Viollet et al. 2012; Zhou et al., 2001). 5-aminoimidazole-4-
carboxamide-1-beta-D-ribofuranoside (AICAR), an AMPK activator, also 
reversed alcoholic fatty liver in rats (Tomita et al., 2005).  Both Metformin and 
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AICAR act on AMPK to provoke similar effects to increase ATP-producing 
pathways and elicit beneficial results (Zhou et al., 2001; Tomita et al., 2005).  
Perfluorinated chemicals (PFCs) have been studied for a couple of decades 
and have multiple detrimental effects in rodents (Lau et al., 2007).    
Specifically, PFOS, According to the Environmental Protection Agency (EPA), 
PFOS is considered to be a hepatotoxicant and obesogen and possible 
carcinogen in humans. There are limited data regarding PFOS effects in 
human related to NAFLD or liver effects.  The C8 Health Project, which has 
studied a cohort of about 47,000 human subjects, and reported a positive 
correlation between serum PFOS and ALT concentration, suggesting liver 
effects (Gallo, 2012).   PFOS administration is described to increase liver 
weight, expression of genes in fatty acid oxidation in rodents (Wan et al., 
2012).  Moreover, PFOS-induced steatosis has been shown to be dose- and 
time- dependent, as observed with increased expression of fatty acid transport 
genes, and decreased expression mitochondrial β-oxidation genes (Wan et 
al., 2012).  Liver weight increases are, in part, attributed to an increase in 
hepatic triglycerides (Bijland et al., 2011).  The reversibility of PFOS-induced 
hepatic lipid accumulation has not been described. 
 
The overall goal of this project was to determine whether PFOS exposure 
interferes with recommended therapies to decrease hepatic lipid content that 
are used to treat NAFLD.  It was hypothesized that PFOS administration could 
interfere with the benefits of CR and metformin potentially through targeting 
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AMPK phosphorylation.  Overall, we present novel findings illustrating that 
PFOS administration concurrent with a modest reduction in caloric intake 
thwarted CR-induced decline in hepatic lipids and improvement in glucose 
tolerance and interfered with metformin-induced glucose lowering effects in 
vitro. 
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MATERIALS AND METHODS 
Animals.  10-week-old male C57BL/6 mice weighing approximately 30 grams 
were purchased from Charles River Laboratories (Wilmington, MA).  The mice 
were housed under a controlled temperature (70-73F) with relative humidity 
(30-70%), lighting (12 h, light-dark cycles) environment and acclimated for 5 
weeks on the standard rodent chow to allow for additional weight gain. At 15 
weeks of age, the mice were then fed a purified rodent chow (AIN-93G Growth 
Purified Diet, TestDiet, St. Louis, MO) and monitored for an additional 5 weeks 
for food consumption to calculate a 25% calorie restriction.  At 21 weeks of 
age, mice were fed either ad libitum (AL) or placed on a 25% caloric restriction 
(CR).  The mice were then divided into two subsequent groups (n=8) that were 
administered tap water as vehicle (Veh) via oral gavage (5 ml/kg) or 
Heptadecaperfluorooctanesulfonic acid (PFOS) potassium salt (100 µg/kg, 5 
ml/kg) purchased from Sigma Aldrich (catalog#77282, Lot#BCBH2834V, St. 
Louis, MO) for 6 weeks.  Body weight and food intake were monitored daily 
and recorded.  Serum, liver, white adipose tissue, and skeletal muscle from 
non-fasted mice were collected, snap frozen with liquid nitrogen, and stored at 
-70°C until analysis. 
 
Glucose tolerance test and insulin tolerance test.  Glucose tolerance (GTT) 
and insulin tolerance tests (ITT) were performed as previously described 
(More et al., 2013; Xu et al., 2012).  The GTT and ITT were performed after 3 
and 4 weeks of CR and PFOS treatment, respectively.  For the GTT, mice 
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were fasted for 12 hours and glucose (1 g/kg, i.p.) was administered.  For ITT, 
mice were fasted for 12 hours and insulin (1 unit/kg, i.p.) was administered.  
Blood glucose was determined by measuring tail blood concentrations at 0, 
15, 30, 60, and 120 min after glucose or insulin administration using a Bayer 
Contour glucometer. 
 
Measurement of cholesterol, triglyceride, free fatty acid, and glucose 
concentration. Cholesterol, triglyceride, and, free fatty acid quantifications 
were performed using colorimetric assay kits from Pointe Scientific Inc. 
(Canton, MI) according to the manufacturer’s protocol. Tissues (50 mg) were 
homogenized with PBS and extracted with chloroform-methanol (2:1; vol/vol). 
The residue was re-suspended in 1% Triton X-100 in 100% ethanol. Lipid 
content was normalized with tissue weight.  Serum glucose concentration was 
measured with a glucose assay kit (Eton Bioscience Inc., San Diego, CA) 
based on manufacturer’s protocol.   
 
RNA isolation and quantitative real-time PCR. Total RNA was isolated using 
TRIzol reagent (Invitrogen, Camarillo, CA) according to the manufacturer’s 
instructions. 1 μg of total RNA was converted to cDNA, and mRNA levels were 
quantified by quantitative real-time PCR using a Roche LightCycler 480 
System (Roche Applied Science, Mannheim, Germany). SYBR green reagent 
was used, and relative target gene expression was normalized to GAPDH 
mRNA. 
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Determination of relative protein expression in liver and skeletal muscle by 
western blot.  Tissues (∼50 mg) were homogenized in 1 ml of RIPA buffer 
containing protease and phosphatase inhibitor.  Protein lysates were 
electrophoretically resolved using polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were resolved by SDS-PAGE (10% resolving and 4% 
stacking gel) and then transblotted onto low fluorescence polyvinylidene 
fluoride membrane (PVDF) (Millipore, Billerica, MA) in transfer buffer at 30V 
overnight.  Antibody blocking conditions, dilutions, incubation conditions, and 
secondary antibodies are described in a supplemental table (Supplemental 
Table 1). PVDF membranes were incubated in blocking solution for 1 hour.  
Next, blots were incubated with primary antibody specific to the protein of 
interest diluted in blocking buffer at either 4°C overnight or room temperature 
for 3 hours.  Primary antibody was removed and the membrane was  washed 
with washed in tris-buffered saline with 0.2% Tween 20 (TBS/T) three times for 
5 min at room temperature. Next, blots were incubated with secondary 
antibody specific diluted in blocking buffer for 1 hour.  The membrane was 
either visualized if infrared detection was used (LiCOR Odessey, Lincoln,NE) 
or incubated in ECL+ chemiluminescent substrate for 5 min (GE Healthcare 
Life Sciences, Pittsburgh, PA) and visualized using light-sensitive film.  The 
relative abundance of protein in each sample was quantified and normalized to 
β-actin.   
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Primary hepatocyte and HepG2 treatment and assay for glucose production. 
Primary mouse hepatocyte isolation.  Primary mouse hepatocytes were 
isolated from livers of adult C57BL/6 mice using a two-step collagenase 
perfusion; 1x106 cells/well in 2 mL completed medium (William’s Medium E 
supplied with 10% FBS) were seeded on collagen-coated 6-well plates. After 
cell attachment (~4 h), they were cultured in serum-free William’s E Media 
containing 1% insulin-transferrin-selenium (ITS) and dexamethasone 
supplement (Invitrogen, CA). Media was then replaced with custom William’s 
Media E lacking glucose and supplemented with pyruvate.  Media was 
collected at time zero to measure glucose output.  Glucagon (100nM), PFOS 
(2.5 µM) or a combination of both, were added to the hepatocytes and media 
was collected at 6 hours to measure glucose output using a glucose assay 
(Eton Bioscience Inc., San Diego, CA). HepG2 cells were treated with PFOS 
(25, 50, and 100 µM), and metformin (1mM) alone or in combination.  Media 
was collected after 6-10 hours after treatment and media glucose 
concentration was assayed using the glucose assay described above.  
 
Adiponectin assay.  The Mouse Adiponectin/Acrp30 Quantikine ELISA Kit was 
purchased from R&D Systems, Minneapolis, MN.  The protocol followed was 
according to the product insert.  Mouse sera was diluted 1:2000 and media 
from cultured adipocytes was diluted 1:2000 before running in the assay. 
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Oil-Red-O Staining. Cells were fixed with 10% buffered formalin for 30 min and 
then stained with Oil red O (ORO) working solution. A fresh working solution 
was prepared by combining 3 parts of stock solution (0.5% ORO in 
isopropanol) with 2 parts of deionized water and then filtered after 15 minutes.  
Cells were incubated in working solution for 15 min at room temperature and 
then ORO solution was removed.  Wells were quickly rinsed 2 times with fresh 
60% isopropanol, washed with water, and mounted in glycerin jelly.  
Quantification includes the addition of 1mL isopropanol to each well then 
140uL of those wells into a 96-well plate for spectrophotometer reading.   
 
Statistical Analysis. 
Power analysis using the sample size calculator 
http://www.jerrydallal.com/LHSP/SIZECALC.HTM was performed with the 
following assumption that the difference in mean between the test and control 
group is 50% of the mean and the standard deviation is 25% of the mean 
values.  Based on this analysis, the sample size used was an n = 8.  
Depending on the analysis, an unpaired Student’s T-test was used or an 
ANOVA followed by a Duncan’s Multiple Range Post Hoc Test.  Significance 
was considered to be p<0.05. 
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Results 
 
Effect of CR and PFOS on body weight, liver weight, and serum 
chemistry.  21-week old male C57BL/6 mice were fed ad libitum or 25% 
calorically restricted for 5 weeks.  In each group, mice were administered 
vehicle (VEH) or 100 µg/kg PFOS daily.  In Figures 1a and b, CR reduced the 
percent body weight from day 0 and the AUC for body weight over time.  Body 
weight and percent weight loss was similar between VEH and PFOS treated 
mice over the course of the study.  CR decreased liver weight by 37.4% and 
WAT tissue by 48.2% (Figures 1C & D).  Liver and WAT weight was similar 
between VEH and PFOS treated groups.  Overall, PFOS administration did 
not significantly alter body or tissue weight, as well as response to CR-induced 
weight loss. 
Serum clinical markers associated with response to weight loss and CR were 
evaluated (Table 1).  CR increased adiponectin levels by 24.2% compared to 
AL fed mice.  In AL fed mice, PFOS also increased adiponectin by 23.4%.  In 
CR fed mice, PFOS did not significantly affect serum adiponectin levels.  CR 
decreased serum glucose by 29.6% compared to AL fed mice.  Interestingly, 
in AL fed mice, PFOS increased serum glucose levels by 65.3% compared to 
AL control.  In CR fed mice, PFOS increased serum glucose levels by 67.3% 
compared to CR mice administered vehicle.   
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PFOS interfered with CR-induced improvement of glucose utilization. 
CR improves glucose tolerance and increases insulin sensitivity (Colman et 
al., 2009; Fontana, 2009).  The effect of PFOS on this CR-induced benefit was 
evaluated. CR decreased glucose levels over time (Figures 2a and b). Overall, 
CR decreased glucose load by 57.9% compared to AL fed mice (Figure 2c).  
In AL fed mice, PFOS administration did not significantly affect response to 
glucose challenge, although the glucose load tended to increase, but did not 
reach statistical significance (p=0.8938) (Figures 2a-c).  Interestingly, PFOS 
administration did affect the response to glucose challenge in mice that were 
placed on CR, with glucose clearance being decreased in CR mice 
administered PFOS (Figure 2a and b).  Compared to CR mice administered 
VEH, glucose load was 74.3% higher in CR mice administered PFOS (Figure 
2c). In CR and AL fed mice, PFOS significantly increased the glucose load 
after 2.5 hours after insulin challenge compared to controls (Figure 2d), 
suggesting that PFOS interferes with insulin suppression of hepatic glucose 
production.  Glucose homeostasis hepatic gene expression was analyzed by 
qPCR.  CR did not markedly decrease Irs1 gene expression levels, however, 
with PFOS, CR fed mice significantly decreased Irs1 gene expression (Figure 
2e).  CR fed mice had decreased hepatic gene expression of Pepck and 
G6pase compared to AL controls (Figure 2e).  In both CR and AL fed mice, 
PFOS significantly decreased Glut2 gene expression (Figure 2e).  Protein 
quantification of phosphorylated-akt was measured within the lysates of 
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skeletal muscle of these mice.  PFOS had no affect on p-akt in either CR or AL 
fed mice (Figure 2f). 
   
PFOS significantly increased lipid content in the livers of mice. 
It has been previously reported that PFOS increased liver weight (Seacat et 
al., 2002; Seacat et al., 2007) and this may be attributable to an accumulation 
of lipids within the liver (Polyzos et al., 2009).  We evaluated the liver histology 
with hematoxylin and eosin (H&E) staining.  CR There is the presence of 
vacuoles in the CR-PFOS treatment group that are not seen in any other 
group (Figure 3a).  PFOS significantly decreased hepatic free fatty acids (FFA) 
by 38.7% in AL fed mice and 39.2% in CR fed mice (Figure 3b).  These data 
are further supported by the significant increase in triglycerides in PFOS-
treated mice.  As expected, CR fed mice had a significant 31.9% decrease in 
hepatic triglycerides compared to AL control (Figure 3c).  Interestingly, PFOS 
significantly increased hepatic triglycerides in both AL and CR fed mice by 
94.9% compared to AL-Veh and 37.6% compared to CR-Veh, respectively 
(Figure 3c). CR fed mice significantly increased hepatic gene expression of 
Cyp4a14 compared to AL fed control (Figure 3d).  PFOS significantly 
increased gene expression in the liver of Cyp4a14 in AL and CR fed mice 
compared to controls (Figure 3d).  PFOS significantly decreased Ppar-α 
hepatic gene expression in both AL and CR fed mice compared to controls 
(Figure 3e).  Downstream targets of Ppar-α were increased upon CR with 
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significant induction of Gpat hepatic gene expression with PFOS exposed CR 
fed mice (Figure 3e).   
 
PFOS alters glucose homeostasis protein expression of mice. 
To better understand whether PFOS was affecting response to CR at the level 
of protein expression, liver lysates were evaluated for changes in protein 
expression.  Western blot analysis of proteins involved in glucose and lipid 
homeostasis was measured (Figure 4a and b).  CR fed mice with PFOS 
administration protein levels were compared to CR fed mice with vehicle 
(Figure 4a).  Phosphorylated-akt is responsible for the uptake of glucose into 
cells and is significantly decreased 38.4% upon PFOS administration in mice 
that underwent CR compared to CR control (Figure 4c). Conversely, 
Phosphoenolpyruvate carboxykinase (Pepck) is the main regulator of 
gluconeogenesis and is significantly increased, both supporting the glucose 
data in Figure 2 (Figure 4c).  Protein levels of P-ampk decreased significantly 
by 34.2% upon PFOS administration with CR compared to control (Figure 4c).  
Protein levels in all groups were compared (Figure 4b).  Cluster of 
differentiation (CD36), also known as fatty acid translocase (FAT), and fatty 
acid synthase (Fas) both increased significantly upon PFOS exposure with CR 
fed mice by over 2-fold and 2.5-fold, respectively, compared to CR control 
(Figure 4d).  Astoundingly, P-ampk significantly decreased over 7-fold in mice 
that underwent CR with PFOS administration compared to CR control (Figure 
4d). 
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PFOS significantly increased glucose within the media of Primary 
Hepatocytes and HepG2 cells. 
Based on our GTT observations, and changes in P-AMPK in liver, the effect of 
PFOS on glucose production in hepatocytes was measured.  Primary 
hepatocytes were isolated from C56BL/6 mice and were treated with 
glucagon, PFOS (2.5uM) and a combination of both for 24 hours.  PFOS 
increased glucose levels in media of primary hepatocytes eliciting a glucagon-
like effect.  Expectedly, glucagon increased glucose within the media of 
HepG2 cells 13-fold compared to vehicle (Figure 5a).  PFOS also increased 
the glucose within the media by 15-fold and taken together, PFOS and 
glucagon treatment increased the glucose within the media by 19.6-fold 
compared to vehicle (Figure 5a). HepG2 cells were treated for 10 hours with 
Metformin (1mM), PFOS (25uM or 100uM) and a combination of both.  
Metformin significantly decreased glucose production in the media of HepG2 
cells by 67.2% compared to DMSO control (Figure 5b).   PFOS (100uM) 
significantly increased glucose within the media by 3.2-fold compared to 
DMSO control (Figure 5b).  When challenged with metformin, PFOS still 
induced glucose output into the media of HepG2 cells by 7-fold compared to 
metformin control (Figure 5b), illustrating that PFOS dampens the Metformin-
induced lowering of glucose within the media.  In a dose-response study with 
HepG2 cells, 5-aminoimidazole, 4-carboxamide ribonucleotide (AICAR) was 
used to stimulate phosphorylation of AMPK and challenged with different 
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concentrations of PFOS (Figure 5c).  PFOS increased glucose production at 
25uM 6-fold compared to DMSO control (Figure 5c).  PFOS (25uM) with 
AICAR increased glucose within the media by 3.5-fold compared to AICAR 
control (Figure 5c).  P-ampk protein levels were analyzed by western blot 
analysis from the lysates of data in Figure 5b.  Metformin increased p-ampk 
while PFOS (25uM) decreased p-ampk protein levels.  When treated with 
metformin and PFOS (25uM), p-ampk levels are greatly decreased compared 
to metformin control (Figure 5d).  
 
PFOS increases glucose within the media of 3T3L1 cells and human 
adipocytes. 
Mature adipocytes were treated with Metformin (1mM) and PFOS (50uM) or in 
combination for 12 hours.  PFOS significantly increased glucose within the 
media of these cells compared to the DMSO control (Figure 6a).  Although 
there is an increasing trend of PFOS with metformin, this is not statistical 
(Figure 6a).  Adiponectin levels were also measured, however, no changes 
were observed among groups (Figure 6b).  Human adipocytes were treated 
with Metformin (1mM), PFOS (50uM) or in combination for 24 hours (Figure 
6c).  PFOS showed an increasing trend of glucose within the media, however 
this is not statistical.  PFOS in combination with Metformin significantly 
decreased the glucose in the media of these cells compared to DMSO control 
(Figure 6c).  Oil-Red-O staining of human adipocytes shows more lipids with 
PFOS treatment compared to DMSO control (Figure 6d). 
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Discussion 
 
NAFLD is a rising worldwide and is associated with obesity and diabetes 
(Masarone et al., 2014).  Diabetes and NAFLD predict the development of one 
another and create a cycle of progression from NAFLD to diabetes and vice 
versa (Williams et al., 2013).  NAFLD is characterized by  >5% of the liver 
made up of fat, lipotoxicity and insulin resistance and thus frequently found in 
people with central obesity or diabetes (Naik et al., 2013; Smith and Adams, 
2011).  Fatty liver is a status of insulin-resistance and responds to treatments 
originally developed for other insulin-resistant states such as Metformin (Ford 
et al., 2015). Obesity is considered to be a predominant risk factor for NAFLD, 
however other etiologies for NAFLD have been hypothesized, such as 
environmental factors (Cave et al., 2007).  The purpose of this study was to 
evaluate whether, PFOS, an environmental chemical associated with adverse 
liver effects would affect the recommended therapeutic strategy to treat 
NAFLD.  Our findings herein illustrate that PFOS dampened the response to 
CR and interfered with metformin-induced glucose consumption.  
 The most beneficial treatment of NAFLD is a low-fat diet and exercise 
(Chalasani et al., 2012). In earlier studies, it is suggested that CR with or 
without exercise decreases liver fat and liver enzymes with no difference 
between CR groups with the CR and exercise groups (Yoshimura et al. 2014; 
Straznicky et al., 2012; Tamura et al., 2005; Larson-Meyer et al., 2008).  It has 
been reported that a 15, 30 and 40% kCal reduction in mice has beneficial 
implications on body weight and hepatic lipids (Zidong and Klaassen, 2013).  
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In our study, mice were placed on a 25% kCal reduction or fed ad libitum for 5 
weeks dosed with vehicle or challenged with 0.1mg/kg/day PFOS.  
Expectedly, our results are consistent with other studies showing significant 
decreases in body, liver and WAT weights with a ~25%kCal reduction 
(Weindruch et al., 1986; Zidong and Klaassen, 2013) which is on the lower 
side of a kCal reduction (ranges from ~25-60%) (Koubova and Guarente, 
2003).  Our glucose tolerance test (GTT) provides evidence for CR increasing 
glucose tolerance and lowering the total glucose load within mice as well as 
significantly decreasing serum and hepatic lipids CR and these results are 
consistent with other studies (Zidong and Klaassen, 2013).  AMPK inhibits 
hepatic glucose and lipid synthesis and induces lipid oxidation to produce 
energy (Nerstedt, 2010).  AMPK is a regulator of hepatic metabolism in energy 
balance by promoting catabolic pathways and inhibiting ATP-consuming 
pathways and is a good target for the treatment of Type II diabetes (Viollet et 
al., 2006).  AMPK activation is implicated for the benefits of glucose and lipid 
metabolism with exercise, weight loss, and use of anti-diabetes drugs (Towler 
et al., 2007).  Expectedly, in our study, CR induced AMPK activation in mice 
compared to AL control.  AMPK is a heterotrimeric serine/threonine protein 
kinase that regulates energy homeostasis in metabolic tissues upon high 
AMP:ATP ratios (Nerstedt, 2010).  
It is known that PFCs elicit fatty liver, but fewer studies address effects of 
PFOS on hepatic lipid accumulation.  To the best of our knowledge, this is the 
first study that has investigated the effects of PFOS on the role of Metformin 
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and AMPK in a calorically restricted diet.  Here, we show that a daily dose of 
PFOS for over five weeks dampens the beneficial lipid loss of CR as well as 
decreasing the ability of Metformin to lower glucose production via AMPK.  
PFOS exposure has been shown to increase serum glucose and insulin levels, 
although not statistically (Wan et al., 2014).  Wan et al. also show a pre-
diabetic phenotype within mice exposed to PFOS (Want et al., 2014).  We 
show the same trend where PFOS exposure leads to increasing glucose 
within the serum of in vivo and in vitro models.  IRS-1 gene expression was 
significantly decreased upon PFOS exposure in mice undergoing CR 
compared to our ad libitum mouse model.  Glut-2 gene expression was 
significantly decreased in both CR and AL mouse models upon PFOS 
exposure, which may be due to glucose-intolerance as seen with the GTT.  In 
this study, we used the C57BL/6 mouse model on a purified diet that 
underwent CR and daily administration of PFOS to assess the effects of PFOS 
on a CR diet via liver physiology.  We recognize that this model is in lean mice 
and is not a true clinical representation of individuals undergoing CR and an 
obese mouse model would be the better representation of studying PFOS 
effects on NAFLD compared to CR mice with PFOS exposure to truly assess 
PFOS liver physiology.  PFOS has been shown to increase body and liver 
weight but has also elicited effects in models in which did not show an 
increase in body or liver weight (Ngo et al., 2014; Nelson et al., 2010).  A study 
showed a decrease in body weight but an increase in liver weight with PFOS 
exposure (Seacat et al., 2003).  Another study showed increased body weight 
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at a lower concentration of 1 mg/kg and increased body weight at higher 
concentrations of 5 and 10mg/kg over 21 days with all concentrations 
increasing the liver weight attributed to the appearance of cellular vacuolations 
(Wan et al., 2012; Kim et al., 2011).  In our model, a sub-chronic dose of 
PFOS did not affect the body or liver weights of mice with or without CR.    
PFOS has been shown to have a positive correlation with serum ALT levels 
(Gallo, 2012) and increased liver weights (Seacat et al., 2014), which may be 
attributable to an accumulation of lipids.  Associations have been made here 
PFOS has increased the number and size of cytoplasmic vacuoles as well as 
and increase in lipid content, concluding the vacuoles contain lipids (Wan et 
al., 2012).  In our study, we show PFOS increasing hepatic triglycerides, 
interfering with the CR-induced lipid loss. H&E staining shows PFOS with CR 
induces the presence of vacuoles compared to any other group and it is 
reasonable to assume that these vacuoles contain lipids.  PFOS induces 
PPAR-α, which is suggested to account for toxicity associated with PFOS 
(Takacs and Abbott, 2007), however, there are PPAR-α independent toxicities 
as well (Rosen et al., 2010).  We show induction of CYP4a14, a downstream 
target of PPAR-α, upon PFOS exposure.   
 
We used Metformin as a treatment in in vitro models because it is used in the 
treatment of Type II diabetes and has been shown to activate AMPK (Zhou et 
al., 2001).  We show that PFOS dampens the beneficial effects of Metformin 
on lowering glucose production via AMPK activation. Our results indicate that 
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PFOS can potentially interfere with AMPK phosphorylation in liver and cells, 
which is relatively new to the field of environmental health.  For example, we 
observed that glucose production was increased in HepG2 cells and 
hepatocytes treated with PFOS.  AMPK suppression is known to induce 
gluconeogenesis via LKB1 down-regulation (Shaw et al., 2005). In a study, 
genetic silencing of LKB1 resulted in nearly a complete loss of AMPK activity 
(Shaw et al., 2005), suggesting LKB1 is necessary for AMPK activation.  
PFOS is suggested to be transported into the liver via Oatp2 or Oatp1d1 
(Popovic et al., 2014; Yu et al., 2011).  The primary transporters required for 
hepatic uptake of Metformin are OCT1 and OCT3 (Zheng et al., 2014).  PFOS 
and Metformin do not utilize the same transporters, suggesting that PFOS may 
inhibit beneficial effects of Metformin downstream.  
Glucose in the media of primary hepatocytes was statistically increased upon 
PFOS and glucagon exposure. Metformin significantly decreased glucose in 
the media while PFOS (100 µM) significantly increased media glucose in 
HepG2 cells after 10 hours of exposure.  A combination of Metformin and 
PFOS 100 µM was increased compared to Metformin alone. Both Metformin 
and AICAR act on AMPK to elicit similar effects to decrease ATP-consuming 
pathways and increase ATP-producing pathways (Zhou et al., 2001; Tomita et 
al., 2005).  Both PFOS (25 µM) and AICAR in combination with PFOS (25 µM) 
significantly increase glucose in media compared to DMSO control in HepG2 
cells.  AICAR with PFOS (25 µM) significantly increases glucose in media 
compared to AICAR alone.  P-AMPK protein levels were measured in HepG2 
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cells treated with PFOS (25 and 50 µM) and Metformin (1mM) where PFOS 
decreases P-AMPK protein levels when co-treated with Metformin, diminishing 
beneficial effects of Metformin. 
 In our study, we present novel findings illustrating that PFOS 
administration concurrent with a modest reduction in caloric intake thwarted 
CR-induced decline in hepatic lipids and improvement in glucose tolerance 
and interfered with metformin-induced glucose lowering effects in vitro.  To the 
best of our knowledge, this is the first study that investigates PFOS effects on 
metformin and AMPK in a calorically restricted diet.  Our results indicate novel 
findings of lowered AMPK levels upon PFOS administration as well as PFOS 
interference with a major pharmacological therapeutic for diabetic intervention. 
 
Conclusion 
 Perfluorooctanesulfonic acid, a fluoro-surfactant previously used as a 
stain repellent and anti-stick material increased hepatic lipids in mice following 
relatively low dose exposures. An increase in hepatic lipids leads to non-
alcoholic fatty liver disease.  A combination of caloric restriction, dietary 
modification, and exercise is the recommended therapy to reverse obesity and 
nonalcoholic fatty liver disease. The ability to mount an effective response to 
caloric restriction required to effectively shift hepatic metabolism to fatty acid 
oxidation depends upon induction of pathways, such as AMP- activated kinase 
(AMPK). We hypothesized that PFOS administration will interfere with CR-
induced reduction of hepatic lipids and improve glucose tolerance.  
Throughout our studies, we found that PFOS increases hepatic lipid content 
  
 
43
and decreases the ability of mice to effectively decrease this lipid content upon 
CR intervention.  In vitro studies have shown that PFOS interferes with CR 
when challenged with Metformin and decreases the ability of Metformin to 
reduce glucose within the media.  PFOS decreases the beneficial effects of a 
calorically restricted diet and interferes with Metformin’s glucose lowering 
effects. 
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Figure 1. Adult male mice were administered vehicle (Water, VEH) or 
perfluorooctane sulfonate (PFOS, 0.1mg/kg/day) and fed ad libitum (AL) or 
placed on 25% kCal caloric restriction (CR) for approximately 6 weeks.  (A) 
Percent change (%) in body weight from day 0 and (B) the AUC of percent 
body weight illustrate that PFOS did not significantly alter CR-induced percent 
weight at the time of necropsy.  In mice that underwent CR, (C) Liver weight 
and (D) white adipose tissue (WAT) weight were not statistically different upon 
PFOS administration compared to vehicle.  Groups without a common letter 
are statistically different (p<0.05). 
 
Figure 2.  Effect of PFOS and CR on glucose homeostasis.  (A) Raw glucose 
tolerance test (GTT) data and (B) percent change (%) in glucose compared to 
time 0.  CR significantly improved glucose clearance at 0.5 and 1 hours, which 
did not occur in mice that underwent CR with PFOS administration.  (C) Total 
glucose load of GTT plotted as an area under the curve (AUC).   PFOS 
significantly increased total glucose load in CR groups.  (D) Raw data of the 
insulin tolerance test (ITT).  The glucose load was not different between 
groups until 2.5 hours where the two PFOS groups had significantly higher 
glucose load compared to controls.  (E) Hepatic mRNA data.  Irs-1 and Glut2 
expression are significantly decreased in mice that underwent CR upon PFOS 
administration.  Glut2 expression was significantly decreased in ad libitum with 
PFOS compared to control.  (F) PFOS did not markedly alter phosphorylated 
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akt protein levels in these mice.  Asterisks (*) represent a statistical difference 
in treatments groups compared to controls.   
 
Figure 3.  PFOS significantly increased hepatic lipid content.  (A) Liver 
histopathology. H&E staining of liver tissue illustrates PFOS increase 
vacuolization in mice that underwent CR compared to control. Hepatic (B) free 
fatty acids (FFA) were statistically decreased upon PFOS administration.  (C) 
Hepatic triglycerides were statistically increased upon PFOS administration.  
(D) Hepatic mRNA of cyp4a14 and (E) ppar-α and downstream targets.  
Cyp4a14 was statistically induced in mice that underwent CR and PFOS 
administration compared to control.  Groups without a common letter are 
statistically different.  
  
Figure 4.  Hepatic protein expression and quantification.  (A) Western blots of 
proteins involved in glucose homeostasis and lipogenesis in mice that 
underwent CR.  (B) Western blots of proteins involved in the CR pathway.  (C) 
PFOS significantly decreased phosphorylated akt protein levels while 
significantly increasing pepck protein levels in mice that underwent CR 
compared to control.  (D) PFOS significantly decreased p-ampk in mice that 
underwent CR compared to control.  Asterisks (*) represent groups that are 
statistically significant compared to control. 
 
  
 
56
Figure 5.  In vitro glucose and protein measurements in primary hepatocytes 
and HepG2 cell lines.  (A) Media glucose measurement in primary 
hepatocytes with treatments of 6 hours with glucagon, PFOS (2.5uM), and in 
combination.  PFOS statistically increased glucose in the media of primary 
hepatocytes.  (B) Media glucose measurement in HepG2 cells with treatment 
of 10 hours with Metformin (1mM), PFOS (25 and 100uM), and a combination 
of Metformin with both concentrations of PFOS.  Metformin significantly 
decreased glucose in the media while PFOS100uM significantly increased 
glucose.  A combination of Metformin and PFOS100uM was significantly 
increased compared to Metformin alone.  *, p<0.05, Metformin compared to 
DMSO; PFOS100um compared to DMSO.  #, p<0.05, PFOS100uM + 
Metformin compared to Metformin alone. (C) Media glucose measurement in 
HepG2 cells with treatments of 24 hours with AICAR (100uM), PFOS 
(0.025uM-25uM) and a combination of AICAR with each PFOS concentration.  
Both PFOS 25uM and AICAR with PFOS25uM significantly increase glucose 
in media compared to DMSO control.  AICAR with PFOS25uM significantly 
increases glucose in media compared to AICAR alone. *, p<0.05, PFOS25uM 
and AICAR compared with DMSO control.  #, p<0.05, AICAR with PFOS25uM 
compared to AICAR alone.  (D) Western blot of P-ampk (n=1) of HepG2 cells 
treated with PFOS (25 and 50uM) and Metformin (1mM).  PFOS decreases p-
ampk protein expression when co-treated with Metformin, diminishing 
beneficial effects of Metformin. 
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Figure 6.  Analysis of glucose homeostasis in mature adipocytes and human 
adipocytes.  3T3L1 cells were treated with Metformin (1mM), PFOS (50uM) 
and a combination.  (A) Media glucose of mature 3T3L1 cells was significantly 
increased upon PFOS treatment.  (B) PFOS significantly increased 
adiponectin levels in mature adipocytes upon PFOS treatment compared to 
control.  (C) Human adipocytes were treated with DMSO, Metformin (1mM), 
PFOS (50uM), and a combination of PFOS with Metformin.  PFOS increased 
the glucose in the media of these cells (p<0.06) and significantly decreased 
glucose when treated in combination with Metformin.  Asterisks (*) represent a 
significant difference compared to control.  (D) Oil-Red-O staining of the 
human adipocytes. Mag.10x.   
  
 
Table 1. Serum Metabolic Measurements.  Adiponectin, cholesterol, free fatty acids, glucose and triglycerides 
measurements of mice after euthanization. 
Parameters Unit AL-VEH CR-VEH AL-PFOS CR-PFOS 
Adiponectin ng/ml 11007.34±596.02 13674.87±459.70* 13579.57±974.31$ 13565.01±668.01# 
Cholesterol mg/dl 120.01±10.92 108.45±14.85 113.95±10.46 98.19±4.64 
FFA μmol/l 0.96±0.15 1.10±0.11 1.15±0.35 1.06±0.10 
Glucose ng/ml 3744.83±155.85 2637.29±210.06* 6189.69±394.14$ 4414.46±162.14#,§ 
Triglycerides mg/dl 172.08±42.49 130.89±17.00 154.63±17.31 137.50±4.31 
 
Eighteen-week old C57Bl/6 mice underwent treatment for approximately six weeks of either water (VEH) or 
Perfluorooctanesulfonic acid (PFOS) administration (0.1mg/kg/day) and fed either ad libitum (AL) or underwent 25% kCal 
caloric restriction (CR).  After euthanization, these parameters were assayed and analyzed.  *, p<0.05, CR-VEH 
compared to AL-VEH control.  $, p<0.05, AL-PFOS compared to AL-VEH control.  #, p<0.05, CR-PFOS compared to AL-
VEH control.  §, p<0.05, CR-PFOS compared to CR-VEH control.   
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ABSTRACT: Perfluorooctanoic acid (PFOA) is a perfluorinated carboxylic acid 
commonly found in the environment.  According to the EPA, low levels of 
PFOA are detectable in the environment and in the blood of the general 
United States population. PFOA administrations cause liver and 
developmental toxicity in rodents and is found in serum and tissues of wildlife 
and humans worldwide. PFOA is a potent activator of peroxisome proliferator 
receptors (Ppars) contributing to oxidative stress and fatty acid oxidation 
pathways in hepatocytes and possibly in adipose tissue (ppar-γ).  Since PFOA 
is extremely ubiquitous and persistent, our hypothesis is that it would increase 
gene expression in adipose tissue of mice in regard to fatty acid oxidation, lipid 
synthesis and antioxidant response. Adult male mice were treated with 1.0 or 
3.0 mg PFOA/kg in corn oil for 7 days.  Adipose tissue was collected and total 
RNA was isolated.  Analysis of mRNA was completed by quantitative PCR.  
mRNA expression between control and PFOA treated mice was similar.  Our 
results indicate PFOA has no affect on adipose tissue of mice after a 7-day 
treatment.  Literature is lacking information regarding PFOA effects in adipose 
tissue.    
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 INTRODUCTION  
 Perfluorooctanoic acid (PFOA) is a synthetic surfactant and is 
expressed in sera throughout the world of humans and animals (EPA, 2009a; 
and Hines, et al. 2009). PFOA is used in the manufacturing process to make 
fluoropolymers with specific properties for various industrial applications 
including fire resistance, water, oil, and grease repellency as well as providing 
non-stick surfaces for cookware (EPA, 2009a).  PFOA is also produced from 
the breakdown of fluorinated telomers such as grease, soil, stain and water 
resistance (EPA, 2009a).  The Environment Protection Agency (EPA) is 
investigating PFOA as a possible toxin to humans due to the presence of an 
closely related PFC, perfluorooctyl sulfonates (PFOS), in the blood of the 
general United States population which raised concern for its persistence in 
the environment, bioaccumulation and toxicity in the late 1990’s (EPA, 2009a).  
Manufacturing of PFOS ceased and the EPA started investigating similar 
chemicals that might elicit comparable apprehensions (EPA, 2009a).  PFOA 
has been investigated since the 1990’s and is known to elicit liver effects 
(hepatomegaly), development toxicant, and carcinogen in rodent models and 
found in serum and tissues of wildlife and humans worldwide with an average 
half-life of 3.5 years in humans (EPA, 2009a; Hines, et al. 2009; Klaunig, et al. 
2003; Tardiff, et al. 2009).  PFOA stimulates similar effects to peroxisome 
proliferating chemicals (PPC), which have been shown to provoke liver cancer 
due to the induction of peroxisome proliferater-activated receptor alpha 
(PPAR-alpha) (Rosen, et al. 2008b).  Calafat et al suggests that men have 
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higher serum concentrations of perfluoroalkyl acid’s (PFAA) than women, and 
the younger population has higher concentrations than the older population 
(Calafat, et al. 2007).  In Danish men, Joensen et al found that higher PFAA 
concentration is associated with fewer normal spermatozoa (Joensen, et al. 
2009). PFOA can cross the placental membrane and has been found in 
umbilical cord blood in levels that are negatively associated with newborn 
weight (Apelberg, et al. 2007).  Human studies of PFOA are limited, however, 
trace amounts of PFOA have been detected in seminal plasma samples, cord 
blood, and low levels in urine associated with high levels of biliary reabsorption 
rates, (Apelberg, et al. 2007; Harada, et al. 2007; and Joensen, et al. 2009). 
Maestri et al found 0.1ng/g PFOA in all human tissue except for adipose 
tissue, where it was 0.2ng/g PFOA in the general population with very low 
exposure of PFOA (Maestri, et al. 2006).   
Since there is cross-talk among the liver tissue with peripheral tissues, if there 
are effects within the liver, then these effects may also affect adipose tissue.  
Some interconnecting enzymes include sterol regulatory element binding 
protein 1 (SREBP1) regulates which genes involved in lipid biosynthesis 
including fatty acid synthetase (FAS) and acetyl co-A carboxylase (ACC1) 
involved in de novo lipogenesis, diacylglycerol acetyltransferase (DGAT), 
glycerol-3-phosphate acyltransferase (GPAT) and lipoprotein lipase (LPL) 
involved in the reesterification of fatty acids, and stearoyl co-A desaturase 
(SCD1) involved in fatty acid desaturation and elongation (Hagen, et al. 2010).  
Peroxisome proliferator-activated receptor alpha (PPAR-alpha) is found 
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predominantly in the liver and is involved in lipid and lipoprotein metabolism 
reducing triglyceride levels as well as maintaining energy homeostasis 
regulating obesity (Tyagi, et al. 2011).  PPAR-gamma targets LPL and is 
involved in lipid metabolism and lipid uptake into the adipocytes and is 
involved in adipocyte differentiation and hypertrophy (Tyagi, et al. 2011).  
Ppar-y is highly expressed within adipose tissue and may be an unrecognized 
target for various industrial or environmental chemicals within society, such as 
PFOA (Malone and Waxman, 1999).   
Nuclear factor-2 p45 related factor 2 (NRF2) is a basic leucine-zipper 
transcription factor that serves as a cellular detoxicant by positively regulating 
over 200 cytoprotective genes that defend against stressors, such as toxic 
chemicals and radiation (Klaassen, et al. 2010; Niture, et al. 2011; Sykiotis, et 
al. 2011; Young-Sam, et al. 2006).  The genes include phase II drug 
metabolizing enzymes and antioxidant proteins (Young-Sam, et al. 2006).  
NRF2 is sequestered in the cytoplasm via Kelch-like ECH-associated protein 
(Keap1) (Giudice, et al. 2010; Young-Sam, et al. 2006).  Upon activation by 
stressors, NRF2 is released from Keap1 and translocates into the nucleus, 
binding to antioxidant response elements (ARE)/electrophile response 
elements (EpREs) in the promoter region and eliciting activation of 
cytoprotective genes (Giudice, et al. 2010; Niture, et al. 2011; Young-Sam, et 
al. 2006).  Keap1 travels into the nucleus binding to NRF2 dissociating it from 
ARE and the complex is exported to the cytoplasm via the nuclear export 
sequence of keap1 (Giudice, et al. 2010).  Natural and synthetic 
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chemopreventive agents induce antioxidative and carcinogen-detoxification 
enzymes via the NRF2/keap1 pathway (Giudice, et al. 2010).  Nrf2 controls 
the basal and inducible expression of mouse and human genes, such as 
NQO1, GCLC, and GSTA1 (Klaassen, et al. 2010; Ramos-Gomez, et al. 
2001).  Oxidative stress is a stressor that activates nrf2/keap1 pathway and 
has been linked to insulin resistance due to the increase in mitochondrial 
reactive oxidative species (ROS) (Yu, et al. 2012).  ROS oxidizes cysteines of 
the keap1 dissociating it from nrf2 allowing the translocation of nrf2 to the 
nucleus (Ray, et al. 2012).  When Nrf2 is activated by known activators on a 
high-fat diet, the increase in adipose tissue mass, hepatic lipid accumulation 
and body-weight was attenuated (Yu, et al. 2012).  However, other studies 
have found conflicting data.  Pi et al. suggest that Nrf2 knockout mice have 
decreased fat mass with more small adipocytes and portray diet-induced 
obesity resistance.  In this same study, Nrf2 knock out mouse embryonic 
fibroblasts (MEF’s) displayed decreased adipogenesis.  In the 3T3-LI cell line 
and human subcutaneous preadipocytes, Pi et al demonstrated adipocyte 
differentiation inhibition with shRNA-mediated nrf2 knockdown possibly 
attributing to the association with, and subsequent decrease of, PPAR-gamma 
expression (Pi, et al. 2010).  Previous data from our lab indicate that in nrf2 
deficiency in Lepob/ob (leptin-deficient-obese) mice induced IR and dyslipidemia 
while decreasing white adipose tissue mass and preventing hepatic lipid 
accumulation indicating a dual role for Nrf2 in metabolic dysregulation (Xu et 
al., 2014).   
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In this study, adult male mice were treated with 1.0 mg PFOA/kg or 3.0 mg 
PFOA/kg in corn oil for 7 days.  We hypothesized that PFOA would alter gene 
expression in adipose tissue of mice in regard to fatty acid oxidation, lipid 
synthesis and antioxidant response.  
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MATERIALS AND METHODS  
Animals and treatment paradigm 
Animal treatment and PFOA dosing we previously used to investigate 
effects PFOA in kidney (Aleksunes, et al. 2013).  Briefly, adult male C57BL/6 
mice were purchased from Charles River Laboratories (Wilmington, WA) and 
fed a normal rodent chow diet (Aleksunes et al., 2013).  The mice were split 
into three groups (n=6); control, low dose PFOS (1.0 mg/kg) and high dose 
PFOS (3.0 mg/kg). Perfluorooctanoic acid (PFOA) (77262, Sigma-Aldrich, St. 
Louis, MO) was administered once per day at a dose volume of 5ml/kg for 
seven days. For 1 mg/kg dose, 2 mg PFOA was dissolved in 1 ml deionized 
(DI) water. This stock was vortexed and 9 ml of DI water was added to make a 
2mg/10 ml solution that was filter sterilized. For 3mg/kg dose, 6 mg PFOA was 
dissolved in 1 ml DI water and vortexed. Then 9 ml DI water was added to 
make a 6mg/10 ml solution, which was filter sterilized.  Organs and tissues 
were collected and snap frozen and stored in -80 until RNA analysis.   
 
PCR Assay 
Total RNA was isolated from the collected adipose tissue by phenol-
chloroform extraction with 1.2mL Trizol (Invitrogen, Camarillo, CA)/100mg 
tissue according to the manufacturer’s protocol.  RNA concentration were 
determined by measuring UV absorbance at 260 nm using NanoDrop™.  The 
total RNA samples were stored at -80°C until further use for analysis.  1 μg of 
total RNA was converted to cDNA, and mRNA levels were quantified by 
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quantitative real-time PCR using a Roche LightCycler 480 System (Roche 
Applied Science, Mannheim, Germany). Genes measured were Acc-1, Scd-1, 
Lpl, Ppar-γ, Srebp-1, Nrf2, Nqo-1, Gclc, Irs-1, Keap-1, and Ahr.  SYBR green 
reagent was used, and relative target gene expression was normalized to 
GAPDH or 36B4 mRNA.    
 
 
 Statistical Analysis 
 Statistical analyses of differences were performed by Student’s t test.  P 
< 0.05 was considered statistically significant.  Unless otherwise stated, all 
data were presented as mean ± SE of five animals. 
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 RESULTS 
 PFOA treatment did not affect body weight, however, did increase 
liver weight. 
 PFOA has been suggested to induce body weight gain in mice, 
however, in our study, the mice did not have and increased average body 
weight compared to the vehicle in either 1.0 mg/kg or 3.0 mg/kg PFOA which 
is illustrated in Figure 1.  It is suggested that mice with PFOA administration 
have increased liver weights due to an accumulation of hepatic triglycerides.  
In our study, there was a statistical increase that is dose-dependent.  The 
white adipose tissue weight was unchanged between groups.  Kidney tissue 
weights were increased with a treatment of 1.0 mg/kg PFOA compared to 
vehicle, but not in the 3.0 mg/kg PFOA treatment.   
  
  PFOA treatment did not affect lipid synthesis and accumulation 
gene expression in white adipose tissue. 
 Srebp1c is the regulator of lipid synthesis and acts on its target genes, 
Scd1 and Acc1.  As shown in Figure 2, Srebp1c mRNA expression was 
significantly increased in both treatment groups, while Scd1 and Acc1 were 
not significantly different among treatment groups; however, Scd1 possesses 
an increasing PFOA dose-dependent trend.   Ppar-α is involved in fatty acid 
oxidation with a downstream target of Cyp4a14.  PFOA is suggested to be an 
agonist for Ppar-α, however, in white adipose tissue with 1.0 and 3.0mg/kg 
PFOA for 7 days, Ppar-α gene expression was not statistically different than 
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that of vehicle.  PFOA treatment did not significantly alter Cyp4a14 compared 
to vehicle.  Lpl codes for lipoprotein lipase which is involved in the breakdown 
of triglycerides to free fatty acids that can be uptaken into tissues, mainly 
skeletal muscle, adipose tissue and cardiac muscle.  PFOA did not 
significantly alter Lpl gene expression in either treatment group compared to 
vehicle.  PPAR-γ is involved in adipocyte differentiation and was not 
significantly altered with PFOA administration.   
  
 PFOA treatment did not affect oxidative stress gene expression in 
adipose tissue 
 Oxidative stress mRNA expression is illustrated in Figure 3.   The 
transcription factor, Nrf2, is sequestered in the cytosol by Keap1 until 
phosphorylation where Nrf2 translocates to the nucleus activating the initiation 
of transcription of its target genes, Ahr and Gsta1.  Nrf2 is significantly 
increased with 1.0 mg/kg PFOA treatment compared to vehicle, however, 3.0 
mg/kg PFOA treatment is not.  Downstream targets of Nrf2 were not 
significantly different among treatment groups.   
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DISCUSSION 
 The purpose of this study was to evaluate the effects of PFOA 
exposure on adipose tissue.  Overall, the findings suggest PFOA does not 
markedly affect adipocyte differentiation, lipid synthesis and accumulation, or 
oxidative stress response in adipocytes.   
 PFOA is structurally similar to a fatty acid and acts similarly as it 
activates nuclear receptors, binds to transporters and carrier proteins and 
interacts with membranes (Post, et al. 2012).  PFOA activates PPAR-alpha 
and other nuclear receptors (Post, et al. 2012).  SREBP-1 was significantly 
increased in the 3mg/kg PFOA treated mice.  SREBP-1 regulates genes 
involved in lipid biosynthesis such as FAS, SCD-1, ACC-1, and LPL (Hagen, 
et al. 2010).  SCD-1 and ACC-1 remained unchanged in all treatment groups, 
however, elicit increasing PFOA-dependent trends.  A recent review suggests 
that effects such as obesity and metabolic changes are not evident until long 
after PFOA has been eliminated from the body, which may be a factor that our 
findings are not statistical, however show slight trends (Post, et al. 2012).  
Also, it is suggested that prenatal PFOA exposure is associated with the 
increased risk of obesity and metabolic hormone differences in 20-year old 
women (Post, et al. 2012).   
 The increase in body weight of mice in a PFOA-dependent manner 
could be due to increases of triglycerides, phospholipids, and cholesterol 
accumulation in the liver, which induced fatty liver in mice caused by PFOA 
administration (Post, et al. 2012).   
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 Other studies report findings primarily based on liver tissue.  Steenland 
et al suggest there is a significant, positive correlation of PFOA and 
cholesterol levels (Steenland, et al. 2010).  Although the mode of action is not 
well understood, PFOA’s action is suggested to be part PPAR-alpha-
dependent and part PPAR-alpha-independent.  PPAR-alpha independent is 
thought to be because the branched isomers of PFOA increased liver weight 
but was less effective in activating PPAR-alpha (Post, et al. 2012). Studies 
suggest that PFOA increases body weight of mice even at low doses of 
0.01mg/kg-0.30mg/kg (Wan et al., 2012; Yan et al., 2014).  Also, in PPAR-
alpha-null mice, PFOA is also hepatotoxic, contributing to the PPAR-alpha-
independent mechanism of PFOA (Post, et al. 2012).  
 The EPA is investigating PFOA for possible toxic effects.  Humans have 
trace amounts of PFOA in serum and tissues (EPA, 2009a).  The endpoints of 
PFOA in humans and experimental animals are usually parallel; however, 
differ in lipid metabolism outcome (Post, et al. 2012). Literature is abundant 
with effects of PFOA in the liver but lacks data in adipose tissue.  This 
preliminary study is one of the first to explore the mechanism of PFOA in 
adipose tissue that may be attributable to its toxic effects. 
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Figure 1.  Overall body and organ weights after PFOA treatment.  (A) Average 
body weight measurements after PFOA administration.  (B) Average liver 
weight measurements after PFOA administration.  *, p<0.05, PFOA treatment 
groups are both statistically higher than the vehicle liver weights.  (C) Average 
white adipose tissue weight after PFOA administration.  (D) Average kidney 
weight measurement after PFOA administration.  *, p<0.05, 1mg/kg PFOA 
administration statistically increased average kidney weights compared to 
vehicle kidney weights.   
 
Figure 2.  Fatty acid oxidation and lipid synthesis gene expression in WAT 
after PFOA administration.  There was no alteration in fatty acid oxidation 
genes (Cyp4a14 and Ppar-a).  PFOA administration significantly increased 
Srebp1c mRNA expression, but did not affect the expression of downstream 
genes (e.g. Acc-1, Lpl, and Scd-1).  Ppar-γ mRNA expression was similar 
between groups with no statistical differences.  *, p<0.05, both PFOA 
treatment groups significantly increased srebp1c gene expression compared 
to vehicle.   
 
Figure 3.  Oxidative stress target gene expression in WAT after PFOA 
administration.  PFOA administration (1 mg/kg) increased nrf2 mRNA 
expression in WAT.  Downstream Nrf2-target genes (e.g. Nqo1, Gclc, Keap1, 
Gsta-1, and AhR) did not show statistical differences between groups. 
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*,p<0.05, nrf2 gene expression was statistically higher in 1mg/kg PFOA 
treatment group compared to vehicle.  
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APPENDICES 
 
Introduction 
Oleanolic Acid Decreased Hepatic Cholesterol Synthesis.  This appendix 
material reflects a study that I helped conduct during my graduate studies.  We 
were not able to find a mechanism to describe the observed phenotype and 
the project was a minor focus of my thesis work.  I performed tissue analysis, 
gene expression, and the western studies.  The overall conclusion of this 
study was that Oleanolic acid decreased hepatic cholesterol synthesis, but the 
mechanism by which it does so was not uncovered.  The appendix material 
provides key data for the study.   
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Introduction  
Oleanolic acid (OA) is a pentacyclic triterpenic acid found in many 
fruits in vegetables as secondary plant products and exists as the free acid 
form eliciting many beneficial nutriceutical properties protecting against 
hepatotoxicants (Prades, 2011; de Melo, 2010; Reisman, 2010).  OA has been 
used in Chinese medicine for the treatment of liver disorders protecting 
against oxidative and electrophilic stress and activates the nuclear factor 
erythroid 2-related factor 2 (Nrf2)/ kelch-like ECH-associated protein-1 
(Keap1) pathway inducing expression of cytoprotectant genes (Resiman, 
2010).  OA is bioactively present in olive leaves, mistletoe sprouts, grape, 
clove, and pomegranate flowers (de Melo, 2010).  Pharmacological and 
biochemical advantages include anti-inflammatory (most attributable to the 
suppression of the inducible nitric oxide synthethase gene), anti-hypertensive 
(OA attenuated endothelial dysfunction), anti-diabetic, anti-viral, anti-
hyperlipidemic (inhibition of the ACAT gene which controls enzymes that 
regulate plasma fatty acid metabolism) and hypoglycemic effects which could 
be attributable to the antioxidant effect (de Melo, 2010). Pentacyclic 
triterpenes also show significant suppression of tumor genesis and inhibit 
tumor formation (Prades, 2011).  OA has exhibited agonistic activity of TGR5, 
a G-protein coupled receptor involved in energy metabolism and is a potential 
drug target candidate due to its suppression of insulin resistance and anti-
obesity effects (Prades, 2011).   
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OA administration significantly increased expression of nrf2 and its 
target genes in wild-type mice including nqo-1, gclc, and ho-1, however, not in 
nrf2-null mice (Reisman, 2010).  OA pretreatment reduces acetaminophen 
hepatotoxicity in nrf2-null mice and more significantly in wild-type mice 
(Reisman, 2010).  
Butylated hydroxyanisole (BHA; 3-tert-butyl 4-hydroxyanisole) is a 
synthetic phenolic compound that has been suggested to be a strong inducer 
of Nrf2 and two of its downstream targets; Nqo-1 and HO-1 in rat hepatocytes 
(Keum  et al., 2006). BHA has been shown to induce glutathione-S-transferase 
(GST) and Nqo-1 activities indicating a cytoprotective mechanism possibly 
through Nrf2 (Hayes et al., 2000).   
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Nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine-zipper 
transcription factor that serves as a cellular detoxicant by endogenously 
positively regulating over two hundred cytoprotective genes that defend 
against stressors, such as toxic chemicals and radiation (Niture, 2011; 
Sykiotis, 2011; Klaassen, 2010; Reisman, 2010; Wang, 2010; Young-Sam, 
2006).  The genes include phase II drug metabolizing enzymes and 
antioxidant proteins (Young-Sam, 2006).  Kelch-like ECH-associated protein 1 
(Keap1) acts as a tether, sequestering nrf2 in the cytoplasm, at low oxidative 
and electrophilic stress level conditions (Reisman, 2010; Giudice, 2010; 
Young-Sam, 2006).  In the cytoplasm under low oxidative and electrophilic 
stress, keap1 is an adapter of Cullin (cul) 3-based E3 ligase which promotes 
nrf2 degradation (Reisman, 2010).  Cul3 acts as a scaffold protein regulating 
transcription factor turnover and consequently facilitates ubiquitination for 
protein degradation (Resiman, 2010).  Upon oxidative stress, nrf2 translocates 
into the nucleus, heterodimerizes with a musculo-aponeurotic fibrosarcoma 
(Maf) protein binding with antioxidant-response elements (AREs)/ electrophile 
response elements (EpREs) upstream at the promoter of cytoprotectant genes 
eliciting cellular defense mechanisms restoring homeostasis between oxidants 
and anti-oxidants (Niture, 2011; Resiman, 2010; Wang, 2010; Giudice, 2010; 
Young-Sam, 2006). Keap1 travels into the nucleus binding to NRF2 
dissociating it from ARE and the complex is exported to the cytoplasm via the 
nuclear export sequence of keap1 (Giudice, 2010).  Natural and synthetic 
chemopreventive agents induce antioxidative and carcinogen-detoxification 
 95 
 
enzymes via the Nrf2/keap1 pathway (Giudice, 2010).  Nrf2-null mice exhibit 
an enhanced susceptibility to hepatic injury (Reisman, 2010; Klaassen, 2010).  
Nrf2 controls the basal and inducible expression of mouse and human genes, 
such as NQO1, HO-1, GCLs, EH-1, GSTs, SRXN-1, MRPs, BSEP, CES, 
SOD1 (Klaassen, 2010; Ramos-Gomez, et al., 2001b).   
 
Hypercholesterolemia: 
Cholesterol is metabolized in two pathways; the classic and the 
alternative (Tiangang, 2009).  CYP7A1is the rate limiting enzyme in the classic 
pathway converting cholesterol to 7-α-hydroxysterol which gets further 
converted to cholic acid and chenodeoxycholic acid and further 
dehydroxylated to produce secondary bile acids, deoxycholic acid and 
lithocholic acid (Tiangang, 2009).  CYP27A1 initiates the alternative pathway 
converting cholesterol to 27-hydroxycholesterol which is further hydroxylated 
by oxysterol 7α-hydroxylase via CYP7B1 (Tiangang, 2009).  Among other 
reasons, cholelithiasis can arise from a decrease in CYP7A1 expression 
leading to less bile acid synthesis and more cholesterol build up in the bile 
creating hard substances, or, gallstones (Biddinger, 2008).  Biliary cholesterol 
and dietary cholesterol diverge to create luminal cholesterol (Tiangang, 2008).  
Luminal cholesterol can be converted to bile acids through CYP7A1 by 7-α-
dehyroxylase or it can be converted to steroids by CYP11A1 (Tiangang, 
2008).  Before the cholesterol can be engulfed into the eneterocytes, it needs 
to unite with bile acids to form micellar cholesterol (Duan, 2007).  The bile 
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micelle is engulfed into the enterocyte through the apical membrane NPC1L1 
(Neimann-Pick C1-like protein 1) transporter (Duan, 2007).   Most of the free 
cholesterol is subsequently esterified through ACAT (acetyl-Coenzyme A 
acetyltransferase) while some is taken back to the liver by the MTP/CM 
(microsomal triglyceride transfer protein/chylomicron) pathway.  The minority 
of cholesterol is excreted through the apical sterol export pump, 
ABCG5/ABCG8 (ATP-binding cassette transporters) heterodimer, from the 
enterocyte into the intestinal lumen and from the hepatocytes into the bile flow 
(Refer to Figure 2) (Rudkowska, 2008).  The ABC superfamily of active 
transporters includes the protein G5 (ABCG5) and protein G8 (ABCG8) which 
are cholesterol half transporters and come together to form a heterodimer that 
functions in the transfer of sterols (Rudkowska, 2008) from enterocytes into 
the intestinal lumen and from hepatocytes into bile for biliary secretion (Ikeda, 
2009; Santosa, 2007; Duan, 2006).  Expression of this heterodimer promotes 
the efflux of cholesterol into the lumen thereby reducing cholesterol absorption 
and consequently resulting in hepatic cholesterol synthesis (Santosa, 2007).  
Phytosterols are also taken up by the NCP1L1 transporter into the enterocyte, 
however, are not esterified and are either transported back into the lumen by 
ABCG5/ABCG8 or go through the ABC1A1 to HDLs and into the periphery 
(Duan, 2006).  Polymorphisms in the genes that encode these transporters 
have the potential to lead to sitosterolemia, hypercholesterolemia (Santosa, 
2007) and gallstone formation (Rudkowska, 2008) by altering their efficacy 
(Santosa, 2007). 
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OA significantly decreased total cholesterol when given a HFD and OA 
compared to the HFD alone (de Melo, 2010).   
 
Study Hypothesis 
The purpose of this study was to demonstrate that an nrf2 activator, oleanolic 
acid, decreased hepatic cholesterol synthesis.   
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Methods 
Animals and Treatments:  Adult C57BL/6 mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  Mice were housed in a temperature-, light-, 
and humidity-controlled environment in cages with corn-cob bedding.  The 
C57BL/6 mice were pair-wise fed i) standard diet (LM-485 Mouse/rat 
sterilizable diet, Harlan Laboratories, Madison, WI) , ii) lithogenic diet (LD, 
15% fat, 1.25% CH, 0.5% sodium cholate, TD03451, Harlan Laboratories, 
Madison, WI), iii) standard diet with butylated hydroxyl anisole (BHA, 0.1% 
w/w) or oleanolic acid (0.1% w/w), iv) LD with butylated hydroxyl anisole (0.1% 
w/w) or oleanolic acid (OA, 0.1% w/w) for 6 weeks, BHA and oleanolic acid 
treatments starting first.  At six weeks, livers and blood were collected.  
 
Lipid Extraction From Liver Tissue: Cholesterol and triglycerides were 
extracted from liver.  First, 150-200 mg of liver tissue was homogenized in a 
15 mL polypropylene tube containing 3 mL of chilled PBS.  200 µL of the 
homogenate was transferred into a second 15 mL polypropylene tube 
preloaded with 3.75 mL of CHCl3 – MeOH (2:1).  The tubes were vigorously 
mixed for 20 seconds, 0.5 mL of distilled water was added, and then mixed 
again for 15 seconds.  The tubes were centrifuged for 5 minutes at room 
temperature and spun at 3000  rpm.  The chloroform layer was transferred into 
a 5 mL glass tube and put into the speed vac1010 set at 45 °C for 2 hours to 
allow the liquid to evaporate.  The lipid residue product was re-suspended in 
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200 µL of Ethanol containing 1% Triton X-100. 
 
Cholesterol and Triglyceride Quantification: Cholesterol and Triglyceride 
quantifications were performed using colorimetric assay kits from Pointe 
Scientific Inc. according to the manufacturer’s protocol. The lipid content was 
quantified indirectly by measuring the amount of formazan dye produced.  
 
RNA isolation and quantitative real-time PCR. Total RNA was isolated using 
TRIzol reagent (Invitrogen, Camarillo, CA) according to the manufacturer’s 
instructions. 1 μg of total RNA was converted to cDNA, and mRNA levels were 
quantified by quantitative real-time PCR using a Roche LightCycler 480 
System (Roche Applied Science, Mannheim, Germany). SYBR green reagent 
was used, and relative target gene expression was normalized to GAPDH 
mRNA. 
 
Western Blots. Sodium dodecyl sulfate polyacrylamide gel electrophoresis was 
used to separate the proteins in each of the samples.  The gel used was a 
10% acrylamide resolving gel with a 4% acrylamide stacking gel.  
Polyvinylidene fluoride membranes were washed in Tris-buffered saline with 
Tween 20 (TBS/T), incubated with primary antibody specific to the protein of 
interest in 2% Non-fat dry milk in TBS/T at 4°C overnight.  The membrane was 
washed again and then incubated with a secondary antibody specific to the 
primary antibody used in 2% Non-fat dry milk in TBS/T for 1 hour.  The 
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membrane was then incubated with ECL+ chemiluminescent substrate (GE 
Healthcare Life Sciences, Pittsburgh, PA) and visualized using light sensitive 
film.  The concentration of the proteins in each sample can be seen by 
quantification of the bands seen in the developed light sensitive film and 
normalized to β-actin.   
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Results 
The effect of oleanolic acid on serum and hepatic cholesterol levels in 
mice. OA has been used in Chinese medicine for the treatment of liver 
disorders protecting against oxidative and electrophilic stress and activates the 
nuclear factor erythroid 2-related factor 2/ kelch-like ECH-associated protein 1 
pathway inducing expression of cytoprotectant genes (Resiman, 2010).  
 
The effect of oleanolic acid feeding on lithogenic diet-induced 
cholesterol uptake, synthesis, and transport gene expression in liver.  
Abcg5/abcg8 is a heterodimer responsible for cholesterol excretion from liver 
to the bile.  Abca1 resides in the basolateral membrane transporting 
cholesterol back into the blood to lipid-poor lipoproteins.  Ldlr is responsible for 
the uptake of cholesterol into the liver and hmg-coar is the rate limiting 
enzyme in which cholesterol is synthesized.  The lithogenic diet alone 
increased abcg5/abcg8 mRNA expression 4-fold.  OA administration with the 
lithogenic diet increased abcg5/abcg8 mRNA expression 3.5-fold.  Abca1 
mRNA expression was increased 2.5-fold on the lithogenic diet alone and 2-
fold with OA on the lithogenic diet.  Ldlr mRNA expression was slightly 
decreased on the lithogenic diet and more decreased with OA administration 
on the lithogenic diet.  Hmg-coaR was decreased 3-fold and 5-fold on the 
lithogenic diet and lithogenic diet with OA respectively.   
 
 102 
 
The effect of oleanolic acid feeding on lithogenic diet-induced bile acid 
uptake, synthesis, and transport gene expression in liver.  Cyp7a1 is the 
rate-limiting enzyme in which cholesterol is converted to bile acids.  Bsep is 
the bile salt export pumped from the liver into the bile.  The lithogenic diet 
alone increased bsep mRNA expression slightly, and even more in the 
lithogenic diet with OA administration.  
 
The effect of oleanolic acid feeding on Nrf2 and Nrf2-target gene 
expression in liver. OA administration significantly increased expression of 
nrf2 and its target genes in wild-type mice including nqo-1, gclc, and ho-1, 
however, not in nrf2-null mice (Reisman, 2010).  
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Conclusion 
OA and BHA are two compounds that are considered to be Nrf2-activators.  In 
In this study, adult male C57BL/6 mice were pair-wise fed ad libitum i) 
standard diet (CONT), ii) lithogenic diet (LD, 15% fat, 1.25% CH, 0.5% sodium 
cholate), iii) standard diet with oleanolic acid (0.1% w/w), iv) LD with oleanolic 
acid (OA, 0.1% w/w) for six weeks.  BHA reduced body weight, however 
increased the liver weights of mice.  BHA treatment doubled serum cholesterol 
levels in mice fed the lithogenic diet compared to mice that received lithogenic 
diet alone.  Mice treated with OA in their diets have similar serum cholesterol 
levels to untreated mice.  However, the overall finding of this study was that 
Oleanolic acid decreased hepatic cholesterol content.   
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Figures. Adult male C57BL/6 mice were pair-wise fed ad libitum i) standard 
diet (CONT), ii) lithogenic diet (LD, 15% fat, 1.25% CH, 0.5% sodium cholate), 
iii) standard diet with oleanolic acid (0.1% w/w), iv) LD with oleanolic acid (OA, 
0.1% w/w) for six weeks. Mice were sacrificed and livers, gallbladders and 
serum were collected.  The serum cholesterol levels were determined by 
colorimetric assay. The cholesterol contents were quantified by measuring the 
amount of formazan dye produced. Asterisks (*) represent a statistical 
difference (p < 0.05) between standard diet and lithogenic diet groups. Double 
Daggers (‡) represent a statistical difference (p < 0.05) between OA and the 
controls.  The lithogenic increased serum cholesterol levels in controls (CONT) 
fed diet only by 40%.  BHA treatment doubled serum cholesterol levels in mice 
fed the lithogenic diet compared to mice that received lithogenic diet alone.  
Mice treated with OA in their diets have similar serum cholesterol levels to 
untreated mice.   
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FIGURE 2 
BHA and OA elevate serum cholesterol levels in C57Bl/6 mice 
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Control OA BHA 
A
v
e
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g
e
    G
e
n
e
    E
x
p
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io
n
    
ABCG5 
Control Diet 
Lithogenic Diet 
0 
0.02 
0.04 
0.06 
0.08 
0.1 
0.12 
0.14 
0.16 
Control OA BHA 
A
v
e
ra
g
e
    G
e
n
e
    E
x
p
re
ss
io
n
    
ABCG8 
Control Diet 
Lithogenic Diet 
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0 
0.05 
0.1 
0.15 
0.2 
0.25 
Control OA BHA 
A
v
e
ra
g
e
    G
e
n
e
    E
x
p
re
ss
io
n
    
FXR Control 
Lithogenic 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
0.045 
Control OA BHA 
A
v
e
ra
g
e
    G
e
n
e
    E
x
p
re
ss
io
n
    
LXR Control 
Lithogenic 
0 
0.0005 
0.001 
0.0015 
0.002 
0.0025 
0.003 
0.0035 
0.004 
Control OA BHA 
A
v
e
ra
g
e
    G
e
n
e
    E
x
p
re
ss
io
n
    
SIRT1 
Control 
Lithogenic 
0 
0.02 
0.04 
0.06 
0.08 
0.1 
0.12 
0.14 
0.16 
0.18 
0.2 
Control OA BHA 
A
v
e
ra
g
e
    G
e
n
e
    E
x
p
re
ss
io
n
    
SREBP1C 
Control 
Lithogenic 
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0 
0.005 
0.01 
0.015 
0.02 
0.025 
0.03 
0.035 
0.04 
Control OA BHA 
Nqo1 
Standard 
Lithogenic 
0 
0.002 
0.004 
0.006 
0.008 
0.01 
0.012 
0.014 
0.016 
Control OA BHA 
Srebp2 
Standard 
Lithogenic 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
Control OA BHA 
Gsta-1 
Standard 
Lithogenic 
0 
0.005 
0.01 
0.015 
0.02 
Control OA BHA 
Fas 
Standard 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
Control OA BHA 
Scd-1 
Standard 
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